Last reviewed · How we verify
HL040XC
At a glance
| Generic name | HL040XC |
|---|---|
| Sponsor | HanAll BioPharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia (PHASE3)
- A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HL040XC CI brief — competitive landscape report
- HL040XC updates RSS · CI watch RSS
- HanAll BioPharma Co., Ltd. portfolio CI